» Articles » PMID: 36110112

Risk Factors Associated with Severe Disease in Respiratory Syncytial Virus Infected Children Under 5 Years of Age

Abstract

Objective: To evaluate risk factors for severe disease in children under 59 months of age hospitalized with respiratory syncytial virus (RSV) infection.

Study Design: We prospectively enrolled 1,096 cases of laboratory confirmed RSV infection during three consecutive RSV seasons in 2015-2018. Potential risk factors for severe disease were retrieved through patient questionnaires and linkage to national health registries. Need for respiratory support (invasive ventilation, bi-level positive airway pressure, or continuous positive airway pressure), and length of stay exceeding 72 h were used as measures of disease severity. Associations were investigated using multivariable logistic regression analyses. Multiple imputation was used to avoid bias and inference induced by missing data.

Results: Risk factors associated with a need for respiratory support included age younger than 3 months of age [aOR: 6.73 (95% CI 2.71-16.7)], having siblings [aOR: 1.65 (95% CI 1.05-2.59)] and comorbidity [aOR: 2.40 (95% CI 1.35-4.24)]. The length of hospital stay >72 h was significantly associated with being younger than 3 months of age [aOR: 3.52 (95% CI 1.65-7.54)], having siblings [aOR: 1.45 (95% CI 1.01-2.08)], and comorbidity [aOR: 2.18 (95% CI 1.31-3.61)]. Sub-group analysis of children younger than 6 months of age confirmed the association between both young age and having siblings and the need for respiratory support.

Conclusion: In a large cohort of children <59 months hospitalized with RSV infection, young age, comorbidity, and having siblings were associated with more severe disease.

Citing Articles

Retrospective Analysis of RSV Infection in Pediatric Patients: Epidemiology, Comorbidities, Treatment, and Costs in Dubai (2014-2023).

Joury J, Al Kaabi N, Al Dallal S, Mahboub B, Zayed M, Abdelaziz M J Health Econ Outcomes Res. 2024; 11(2):133-144.

PMID: 39575134 PMC: 11580195. DOI: 10.36469/001c.123889.


Burden of RSV among inpatients with lower respiratory tract infection under 5 years of age: A 10-year retrospective study in Southwest China from 2009 to 2019.

Li T, Fang H, Liu X, Deng Y, Zang N, Xie J Chin Med J Pulm Crit Care Med. 2024; 2(3):182-187.

PMID: 39403415 PMC: 11471105. DOI: 10.1016/j.pccm.2024.08.006.


Factors associated with severe respiratory syncytial virus infection among hospitalized children in Thammasat University Hospital.

Bunjoungmanee P, Sompoch S, Tangsathapornpong A, Kulalert P F1000Res. 2024; 13:231.

PMID: 39055881 PMC: 11269972. DOI: 10.12688/f1000research.146540.2.


Respiratory syncytial virus in pediatric patients admitted to a tertiary center in Amman: clinical characteristics, and age-related patterns.

Al-Iede M, Alhouri A, Marwa K, Alnajjar R, Abuzenah M, Abu-Hussein B BMC Pediatr. 2024; 24(1):334.

PMID: 38750503 PMC: 11095006. DOI: 10.1186/s12887-024-04799-8.


Pre-COVID-19-pandemic RSV epidemiology and clinical burden in pediatric primary care in Italy: a comparative analysis across two regions for the 2019/2020 season.

Pandolfi E, Loconsole D, Chironna M, van Summeren J, Paget J, Raponi M BMC Infect Dis. 2024; 24(1):388.

PMID: 38605310 PMC: 11007985. DOI: 10.1186/s12879-024-09229-9.


References
1.
Bezerra P, Duarte M, Britto M, Correia J . Severity of viral coinfection in hospitalized infants with respiratory syncytial virus infection. J Pediatr (Rio J). 2011; 87(5):461. DOI: 10.2223/JPED.2149. View

2.
Hall C, Simoes E, Anderson L . Clinical and epidemiologic features of respiratory syncytial virus. Curr Top Microbiol Immunol. 2013; 372:39-57. DOI: 10.1007/978-3-642-38919-1_2. View

3.
Sun Y, Lopez C . The innate immune response to RSV: Advances in our understanding of critical viral and host factors. Vaccine. 2016; 35(3):481-488. PMC: 6060409. DOI: 10.1016/j.vaccine.2016.09.030. View

4.
Grimwood K, Cohet C, Rich F, Cheng S, Wood C, Redshaw N . Risk factors for respiratory syncytial virus bronchiolitis hospital admission in New Zealand. Epidemiol Infect. 2008; 136(10):1333-41. PMC: 2870733. DOI: 10.1017/S0950268807000180. View

5.
Modjarrad K, Giersing B, Kaslow D, Smith P, Moorthy V . WHO consultation on Respiratory Syncytial Virus Vaccine Development Report from a World Health Organization Meeting held on 23-24 March 2015. Vaccine. 2015; 34(2):190-197. PMC: 6858870. DOI: 10.1016/j.vaccine.2015.05.093. View